Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Medicare Coverage for Novel Technologies Slow and Lacking, Say Stanford Researchers

  • Post author:PacConAdmin
  • Post published:August 4, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Only 28 out of 64 medical device and diagnostic technologies, or 44 percent, requiring new Medicare coverage received reimbursement from 2016 to 2019, with the median time to at least…

Continue ReadingMedicare Coverage for Novel Technologies Slow and Lacking, Say Stanford Researchers

Regulatory Update — Week of Aug. 7, 2023

  • Post author:PacConAdmin
  • Post published:August 4, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Over the past week, the FDA issued final guidance for waivers, exceptions, and exemptions from Section 582 of the FD&C Act, draft guidance for previously approved antiretrovirals for treatment of…

Continue ReadingRegulatory Update — Week of Aug. 7, 2023

Regulatory Update — Week of July 31, 2023

  • Post author:PacConAdmin
  • Post published:August 4, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Over the past week, the FDA issued final guidance for waivers, exceptions, and exemptions from Section 582 of the FD&C Act, draft guidance for previously approved antiretrovirals for treatment of…

Continue ReadingRegulatory Update — Week of July 31, 2023

Nitrosamines Guidances Published by the FDA and EMA

  • Post author:PacConAdmin
  • Post published:August 4, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA and the European Medicines Agency (EMA) have both issued guidances on various aspects of detecting, measuring, limiting and avoiding the presence of nitrosamine impurities in pharmaceuticals. Source: Drug…

Continue ReadingNitrosamines Guidances Published by the FDA and EMA

FDA Finding of ER Lamotrigene Bioequivalence Opens Doors for More Generics

  • Post author:PacConAdmin
  • Post published:August 4, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

An extended-release (ER) generic lamotrigine, used to treat epilepsy, is bioequivalent to GSK’s Lamictal, the FDA has determined — a finding that opens the way for pharmacy-level substitution of any…

Continue ReadingFDA Finding of ER Lamotrigene Bioequivalence Opens Doors for More Generics

CDRH Is Setting a “New Normal” for Conducting Business Post-Pandemic

  • Post author:PacConAdmin
  • Post published:August 4, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

CDRH is accepting and holding in-person meetings with stakeholders and also offering hybrid in-person and virtual – meeting options, Director Jeff Shuren said in a statement Wednesday updating the industry…

Continue ReadingCDRH Is Setting a “New Normal” for Conducting Business Post-Pandemic

Warning Letter: FDA Warns Company That No Longer Manufacturers Drugs

  • Post author:PacConAdmin
  • Post published:August 3, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

LXR Biotech received a warning letter from the FDA for having methods, facilities, controls for manufacturing, processing or holding its drug product that do not conform to GMPs, after the…

Continue ReadingWarning Letter: FDA Warns Company That No Longer Manufacturers Drugs

Recall: Cardiac Panels Could Cause Delayed Diagnosis or Missed Myocardial Infarction

  • Post author:PacConAdmin
  • Post published:August 3, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Quidel Cardiovascular’s recall of Quidel Triage Cardiac Panels, used to diagnose a heart attack, has been deemed class I by the FDA, the most serious type of recall as use…

Continue ReadingRecall: Cardiac Panels Could Cause Delayed Diagnosis or Missed Myocardial Infarction

Form 483: Poor Aseptic Procedures and Dirty Bathrooms Get Iso-Tex Drugmaker Cited

  • Post author:PacConAdmin
  • Post published:August 3, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA slapped Iso-Tex with a Form 483 following a Jan. 30 – Feb. 10 inspection because the radiopharmaceutical manufacturer failed to prevent microbiological contamination of drug products at its…

Continue ReadingForm 483: Poor Aseptic Procedures and Dirty Bathrooms Get Iso-Tex Drugmaker Cited

Form 483: Stryker Dinged for Failure to Make Medical Device Reports

  • Post author:PacConAdmin
  • Post published:August 3, 2023
  • Post category:Uncategorized
  • Post comments:0 Comments

Stryker received an FDA Form 483 after a Jan. 17-24 inspection of its Portage, Mo., plant showed that the company did not have a formal unit to receive, review and…

Continue ReadingForm 483: Stryker Dinged for Failure to Make Medical Device Reports
  • Go to the previous page
  • 1
  • …
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.